Clinicopathological characteristics and prognosis of stage IV colorectal cancer

Miyoshi, Norikatsu; Ohue, Masayuki; Shingai, Tatsushi; Noura, Shingo; Sugimura, Keijiro; Akita, Hirofumi; Gotoh, Kunihito; Motoori, Masaaki; Takahashi, Hidenori; Kutsukake, Kentaro; Okami, Jiro; Marubashi, Shigeru; Fujiwara, Yoshiyuki; Higashiyama, Masahiko; Yano, Masahiko

doi:10.3892/mco.2015.598

Cited by 16 publications

(11 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…CRC is one of the most common malignant cancers, with ~20% distant metastasis and a low 5-year survival rate [ 19 ]. CRC initiation can attribute chromosomal instability, aberrant DNA methylation, and microsatellite instability [ 20 ].…”

Section: Discussionmentioning

confidence: 99%

CBX8 and CD96 Are Important Prognostic Biomarkers of Colorectal Cancer

Song

Tang

et al. 2018

Med Sci Monit

View full text Add to dashboard Cite

BackgroundColorectal cancer (CRC) is one of the most common malignancies worldwide, with high morbidity and mortality rates. The purpose of this study was to identify potential biomarkers in the progression of CRC.Material/MethodsGene and isoform expression datasets of CRC was downloaded from The Cancer Genome Atlas (TCGA). EBSeq of R was used for the normalization of gene and isoform expression, as well as the identification of differential expression genes (DEGs) and isoforms (DEIs) of CRC samples compared with normal samples. The enriched functions of DEGs and DEIs were obtained based on the Database for Annotation, Visualization and Integrated Discovery (DAVID). An independent dataset, GSE38832, was downloaded from the Gene Expression Omnibus (GEO) database for survival analysis of genes with sustained decreased/increased expression values at both gene and isoform levels with the development of CRC.ResultsA total of 2301 genes and 4241 isoforms were found to be significantly differentially expressed in stage I–IV CRC samples. They are closely associated with muscle or cell system activity. Sixteen genes were screened out with sustained decreased/increased expression values at both gene and isoform levels with the development of CRC. Aberrant CBX8 and CD96 expressions were found to be significantly associated with CRC survival.ConclusionsThrough combined analysis of gene and isoform expression profiles, we identified several potential biomarkers that may play an important role in the development of CRC and could be helpful in its early diagnosis and treatment.

show abstract

Section: Discussionmentioning

confidence: 99%

CBX8 and CD96 Are Important Prognostic Biomarkers of Colorectal Cancer

Song

Tang

et al. 2018

Med Sci Monit

View full text Add to dashboard Cite

show abstract

“… 6 7 We also reported clinicopathological characteristics of stage IV CRC. 8 However, it is difficult to determine the benefits of concurrent curative resection for primary and metastatic sites, and predict the prognosis.…”

Section: Introductionmentioning

confidence: 99%

Novel prognostic prediction models for patients with stage IV colorectal cancer after concurrent curative resection

et al. 2016

View full text Add to dashboard Cite

BackgroundWe developed a prediction tool for recurrence and survival in patients with stage IV colorectal cancer (CRC) following surgically curative resection.Patients and methodsFrom January 1983 to December 2012, 113 patients with CRC and synchronous liver and/or lung metastatic CRC were investigated at the Osaka Medical Center for Cancer and Cardiovascular Diseases. All patients underwent curative resection of primary and metastatic lesions. In the group of patients who underwent surgery from 1983 to 2008, a Cox regression model was used to develop prediction models for 1-year, 3-year and 5-year cancer-specific survival (CSS) and relapse-free survival (RFS). In the other group of patients who underwent surgery from 2009 to 2012, the developed prediction model was validated.ResultsUnivariate analysis of clinicopathological factors showed that the following factors were significantly correlated with CSS and RFS: preoperative serum carcinoembryonic antigen level, tumour location, pathologically defined tumour invasion and lymph node metastasis, and synchronous metastatic lesions. Using these variables, novel prediction models predicting CSS and RFS were constructed using the Cox regression model with concordance indexes of 0.802 for CSS and 0.631 for RFS. The prediction models were validated by external data sets in an independent patient group.ConclusionsWe developed novel and reliable personalised prognostic models, integrating tumour, node, metastasis (TNM) factors as well as the preoperative serum carcinoembryonic antigen level, tumour location and metastatic lesions, to predict patients' prognosis following surgically curative resection. This individualised prediction model may help clinicians in the treatment of postoperative stage IV CRC following surgically curative resection.

show abstract

“…Several studies [20][21][22][23][24][25][26][27][28] have reported that the TNM classification has significant prognostic value for stage IV colorectal cancer. Specifically, the type, number and spread of metastatic organs affect the prognosis of patients with stage IV disease.…”

Section: Discussionmentioning

confidence: 99%

Prognostic and predictive values of tumour budding in stage IV colorectal cancer

Nagata¹,

Shinto²,

Yamadera³

et al. 2020

BJS Open

View full text Add to dashboard Cite

Background: Tumour budding is an important prognostic feature in early-stage colorectal cancer, but its prognostic significance in metastatic disease has not been fully investigated. Methods: Patients with stage IV disease who had primary colorectal tumour resection without previous chemotherapy or radiotherapy from January 2000 to December 2018 were reviewed retrospectively. Budding was evaluated at the primary site and graded according to the criteria of the International Tumor Budding Consensus Conference (ITBCC) (BD1, low; BD2, intermediate; BD3, high). Patients were categorized by metastatic (M1a, M1b) and resectional (R0/R1, R2/unresected) status. Subgroups were compared for overall (OS) and recurrence-free (RFS) survival in R0/R1 subgroups; R2/unresected patients were evaluated for the rate of tumour progression, based on change in tumour size from baseline. Results: Of 371 patients observed during the study, 362 were analysed. Patients with BD3 had a lower 5-year OS rate than those with BD1 + BD2 (18⋅4 versus 40⋅5 per cent; P < 0⋅001). Survival analyses according to metastatic and resection status also showed that BD3 was associated with shorter OS than BD1 + BD2. In multivariable analysis, BD3 (hazard ratio (HR) 1⋅51, 95 per cent c.i. 1⋅11 to 2⋅10; P = 0⋅009), T4 status (HR 1⋅39) and R2/unresected status (HR 3⋅50) were associated with decreased OS. In the R0/R1 subgroup, the 2-year RFS rate was similar for BD3 and BD1 + BD2 according to metastatic status. There was no significant difference between BD3 and BD1 + BD2 for change in tumour size in the R2/unresected subgroup (P = 0⋅094). Of 141 patients with initially unresectable metastases who had chemotherapy, 35 achieved conversion from unresectable to resectable status. The conversion rate was significantly higher for BD1 + BD2 than for BD3 (36 versus 18 per cent; P = 0⋅016). Conclusion: Stage IV colorectal cancer with high-grade tumour budding according to ITBCC criteria correlates with poor prognosis.

show abstract

Clinicopathological characteristics and prognosis of stage IV colorectal cancer

Cited by 16 publications

References 17 publications

CBX8 and CD96 Are Important Prognostic Biomarkers of Colorectal Cancer

CBX8 and CD96 Are Important Prognostic Biomarkers of Colorectal Cancer

Novel prognostic prediction models for patients with stage IV colorectal cancer after concurrent curative resection

Prognostic and predictive values of tumour budding in stage IV colorectal cancer

Contact Info

Product

Resources

About